Additionally, the contrasting performance of IL-6 antagonists, which have shown limited effectiveness in bacterial infections but more success in COVID-19 clinical trials, further illustrates how the efficacy of treatments can vary according to the type of infection [59,133,134]. The gene discussed is IL6; the disease is infection.